Menu

Past studies

Browse through some of our past studies

  • HN-2

    Disease

    Head and Neck Squamous Cell Carcinoma (HNSCC)

    Type and Number of Samples

    • Prospective
    • Matched Fresh Tissue and Whole blood (or PBMCs), 10 subjects

    Specific Requirements

    • All subtypes accepted
    • Subjects confirmed positive for HPV 16for HPV 16
    • Samples from biopsies and surgical resections accepted
    • Minimum weight of 100 mg resected tumor tissue or at least 3 core needle biopsies (CNBs) per subject
    • Minimum of 40 ml whole blood or 40 x 106 PBMCs per subject with at least 70% viability upon recovery
    • Subjects confirmed negative for HIV/HCV/HBV

    Associated Data Required

    • Age, Gender, Ethnicity
    • Sample collection date
    • HPV 16 expression status
    • Sample type (e.g. resection or CNB)
    • For whole blood: volume of sample (ml)
    • For PBMCs: number of cells per subject
    • Tumor stage and grade
    • Treatment history (if not treatment-naïve)
    • Available mutation status information (e.g. TP53, CDKN2A, PTEN, PIK3CA, and HRAS)
  • SC-2

    Disease

    Melanoma

    Type and Number of Samples

    • Prospective
    • 1 subject, matched samples
    • Freshly resected tumor tissue (> 1 g) and Whole blood, (> 20 mL, collected in K2 EDTA tubes)

    Specific Requirements

    • Pathology confirmed diagnosis
    • Any stage, Any subtype
    • Primary and secondary (i.e. metastatic) tumors accepted
    • No recent chemotherapy treatment: subjects must be treatment naïve or must have received chemotherapy more than 6 weeks prior to sample collection

    Associated Data Required

    • Age, Gender, Ethnicity
    • Sample collection date
    • Stage (TNM) and grade
    • Tumor size and location (if information on metastases is available)
    • HIV, HCV and HBV status
  • HN-1

    Disease

    Head and Neck Squamous Cell Carcinoma (HNSCC)

    Type and Number of Samples

    • Retrospective
    • FFPE blocks, 40 subjects
    • 5 subjects with Stage I HNSCC
    • 5 subjects with Stage II HNSCC
    • 5 subjects with Stage III HNSCC
    • 15 subjects with Stage IV HNSCC
    • 10 subjects with any stage HNSCC

    Specific Requirements

    • For Stage IV HNSCC: minimum of 10 subjects for which samples were collected from secondary tumor tissue (e.g. lung, liver, skin)
    • For any stage HNSCC: samples from recurrent primary tumor tissue
    • Subjects for all groups must be positive for HPV 16
    • Tumor content ≥ 30%
    • Necrosis ≤ 30%

    Associated Data Required

    • Age, Gender
    • Year of collection
    • Type of sample collection (primary or secondary site)
    • Collecting site (eg. skin, brain, lung, liver)
    • Sample type (e.g. resection or biopsy)
    • Histological subtype
    • Tumor stage and grade
    • HPV 16 status
    • % tumor and % necrosis per sample
  • OC-10

    Disease

    Breast cancer (non-fatty lymph nodes only) / Ovarian Cancer / Cervical Cancer / Uterine Cancer

    • Colorectal cancer / H&N cancer /Gastric Cancer / Liver Cancer / Pancreatic Cancer (PDAC)
    • Lung Cancer
    • Renal cell carcinoma (RCC) / Bladder cancer

    Type and Number of Samples

    • Prospective
    • 20 subjects, matched samples.
    • Tumor tissue (minimum of 500mg), Lymph nodes (minimum 300 mg), 2 red-cap whole blood tubes

    Specific Requirements

    • Lymph nodes to be processed following the protocol provided by the study sponsor to isolate LN-derived Mononuclear Cells (LNs should be tumor free: soft by palpation) - Minimum of 10x106 Mononuclear Cells per case
    • Whole blood to be processed to serum
    • Therapy Naïve, post-neoadjuvant therapy, at relapse
    • 70% recovery (number of cells) and 70% viability at the following steps: post-isolation (PI), pre-freeze (PF), QC (quality control) post-thaw (PT) at provider’s facility

    Associated Data Required

    • Age, Gender, Ethnicity
    • Medical History
    • Concurrent disease(s)
    • Current medication provided with each patient along with de-identified pathology report
  • PT-1

    Disease

    Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

    Type and Number of Samples

    • Retrospective
    • FFPE blocks, 20 subjects

    Specific Requirements

    • Metastatic (secondary) tumor tissue resections only

    Associated Data Required

    • Age, Gender, Ethnicity
    • Sample collection date
    • Pathological diagnosis with microscopic description (histologic subtype)
    • Tumor stage and grade (Gleason scoring)
  • BUO-9

    Disease

    Epithelial Ovarian Cancer

    Type and Number of Samples

    • Prospective
    • Matched samples: Freshly resected tumor tissue (> 1 g) and Matched whole blood (> 20 mL, collected in K2 EDTA tubes), 1 subject

    Specific Requirements

    • Pathology confirmed diagnosis
    • Any stage and subtype accepted
    • Primary or metastatic tumors accepted
    • No recent chemotherapy treatment: subjects must be treatment naïve or must have received chemotherapy more than 6 weeks prior to sample collection tumor subtypes of epithelial origin only

    Associated Data Required

    • Age, Gender, Ethnicity
    • Sample collection date
    • Stage (TNM) and grade
    • Tumor size and location (if information on metastases is available)
    • HIV, HCV and HBV status
  • BUO-8

    Disease

    Breast Cancer

    • Triple Negative Breast Cancer (TNBC)

    Type and Number of Samples

    • Retrospective
    • FFPE blocks Matched blocks from pre-treatment (biopsy) and post-treatment (resection), 5 sets

    Specific Requirements

    • Confirmed diagnosis of TNBC (HER2 negative, ER negative, PR negative)
    • Any histological subtype and any stage accepted
    • Primary and/or metastatic tumors

    Associated Data Required

    • Age, Gender
    • Sample collection date
    • Origin/Site of tumor
    • ER, PR, and HER2 status
    • Tumor Stage (TNM) and Grade
    • Treatment history
  • BUO-7

    Disease

    Endometrial Cancer

    Type and Number of Samples

    • Retrospective
    • FFPE blocks Matched blocks from pre- and post-treatment, 18 sets

    Specific Requirements

    • Any histological subtype and any stage accepted
    • Primary tumors only for pre-treatment FFPE blocks
    • Both primary and/or metastatic tumors accepted for post-treatment FFPE blocks
    • Minimum tumor content: 30%

    Associated Data Required

    • Age, Gender
    • Diagnosis with histopathological subtype
    • Date of pre-treatment biopsy/resection
    • Date of post-treatment biopsy/resection
    • Stage (TNM)
    • Treatment history
  • BUO-6

    Disease

    Breast Cancer

    Type and Number of Samples

    • Prospective
    • EDTA Plasma, 10 subjects

    Specific Requirements

    • Primary or recurrent cancer
    • Subjects who did not yet undergo any surgery, chemotherapy, radiation or any other treatment for this cancerous lesion (including, but not limited to systemic therapies)
    • Recent cancer staging should be within 90 days prior to baseline visit
    • Samples from all stages of cancer will be accepted

    Associated Data Required

    • Age, Gender, Ethinicity
    • Sample collection date
    • Height (cm), Weight (kg)
    • Method of diagnosis (Screening program/Symptoms suggestive of cancer/Following incidental findings/Other-specify)
    • Smoking status
    • CBC (Complete Blood Count), Hemoglobin level (g/dL), Mean Corpuscular Volume (MCV), Ferritin level
    • Presence of comorbidity:Chronic kidney disease, Renal failure • Cirrhosis (if yes – what is the reason? Alcohol, HBV, HCV), Diabetes, COPD, Autoimmune disease (if yes – which?)
    • Family history of cancer
  • BUO-5

    Disease

    Breast Cancer

    Type and Number of Samples

    • Retrospective
    • FFPE slides, 5 subjects

    Specific Requirements

    • Stage III or IV only
    • Treated or untreated
    • Resections and biopsies
    • Primary tumors only
    • Any histopathological subtype
    • Tumor content ≥ 30 %

    Associated Data Required

    • Age, Gender, Ethinicity
    • Sample collection date
    • Histological subtype
    • Pathological diagnosis
    • Tumor stage and grade
    • ER/HER2 status
  • IO-1

    Disease

    Anti-PD1 Therapy Patients

    • Non-Small Cell Lung Cancer (NSCLC)

    Type and Number of Samples

    • Prospective
    • Plasma - 10 subjects

    Specific Requirements

    • Subjects diagnosed with Non-Small Cell Lung Cancer (NSCLC), Renal cancer or other solid tumors
    • Subjects who are going to receive anti-PD1 therapy with prospective clinical follow up

    Associated Data Required

    • Age, Gender
    • Diagnosis
    • Sample collection date
  • IO-2

    Disease

    Immunotherapy Treated Patients

    • Melanoma or Non-Small Cell Lung Cancer

    Type and Number of Samples

    • FFPE Blocks - 50 subjects
    • Prospective

    Specific Requirements

    • Subjects diagnosed with Non-Small Cell Lung Cancer (NSCLC) or Melanoma
    • Immunotherapy treated patients, preferentially with an equal distribution for MSI-H and MSS cases (IHC, Promega or equivalent methodology)

    Associated Data Required

    • Age, Gender
    • TNM staging
    • Follow-up status (relapse, survival)
    • Date of initial diagnosis
    • Sample collection date
    • Details of administered immunotherapy
    • MSI status and Reference test used for MSI characterization
    • Pathological diagnosis (Cancer Type and stage)
    • Samples characterization data (total area, total tissue area, and % tumor or tumor area)
  • IO-3

    Disease

    Anti-PD1 Therapy Patients

    • Non-Small Cell Lung Cancer (NSCLC) - adenocarcinoma subtype

    Type and Number of Samples

    • Retrospective
    • FFPE Slides - 50 subjects
    • 3 groups: * Responders to anti-PD1 therapy; * Responders to ati-PD1 therapy relapsing within 6 months of treatment; * Non-responders

    Specific Requirements

    • Subjects treated with pembrolizumab (Keytruda) or nivolumab (Opdivo) (or other anti-PD1 monoclonal antibodies)
    • FFPE samples (preferably surgical resection material) collected within max of 12 months prior to therapy with anti-PD1; other previous treatments are acceptable (radio- and chemo-therapy)

    Associated Data Required

    • Age, Gender
    • Basic pathology data
    • Medications and treatments with dates
    • At least 12 months clinical follow up data
    • Overall survival and progression survival
    • Data on relapse
    • Sample collection date
  • IO-4

    Disease

    Anti-PD1 Therapy Patients

    • Renal Cell Carcinoma

    Type and Number of Samples

    • FFPE Blocks - 10 subjects
    • Retrospective

    Specific Requirements

    • Subjects treated with Pembrolizumab (Keytruda) or nivolumab (Opdivo)
    • FFPE blocks (resection or biopsy) collected within 12 months prior to therapy
    • Other previous treatments are acceptable

    Associated Data Required

    • Age, Gender, Ethnicity, Race and BMIN
    • Basic Pathological data
    • Medications and treatments
    • At least 24 months clinical follow up data
    • Overall survival and progression-free survival by RECIST criteria
    • Data on relapse
  • IO-5

    Disease

    Anti-PD1 Therapy Patients

    • Non-Small Cell Lung Cancer (NSCLC)
    • Subtypes: Adenocarcinoma; Squamous Cell Carcinoma; Large Cell Carcinoma; Clear Cell Carcinoma; Adenosquamous Carcinoma

    Type and Number of Samples

    • Retrospective
    • FFPE Blocks - 90 subjects

    Specific Requirements

    • Primary tumor
    • Subjects without EGFR mutations
    • PD-L1 positive cases (cut-off: 1%)

    Associated Data Required

    • Age, Gender, Ethnicity
    • Sample collection date
    • Pathological diagnosis with microscopic description and subtype
    • Tumor Stage and Grade
    • Origin/Site of tumor
    • Confirmation of wild type EGFR
    • PD-L1 score
    • Other IHC available data (i.e. TTF-1, P40, and when applicable: chromogranin A and synaptophysin)
    • % tumor and % necrosis per sample
  • IO-6

    Disease

    Anti-PD1 Therapy Patients

    • Non-Small Cell Lung Cancer (NSCLC)
    • Head and Neck Squamous Cell Carcinoma (HNSCC)
    • Upper tract transitional cell carcinoma (UTCC)

    Type and Number of Samples

    • Retrospective
    • FFPE Slides - 40 subjects per indication
    • Sets of 3-5 FFPE tissue sections

    Specific Requirements

    • Subjects must have been treated with anti-PD-1 drugs (i.e. Opdivo® or Keytruda®)
    • Ideally, 20 % of the subjects respond to anti PD-1 treatment (partial response or complete response)
    • Samples from biopsies or surgical resections
    • Tissue collected prior to anti-PD1 treatment
    • Tissue samples fixed in 10 % Neutral Buffered Formalin (NBF)

    Associated Data Required

    • Age, gender
    • Year of collection
    • Pathological diagnosis with microscopic description (histological subtype)
    • Tumor stage and grade
    • Treatment history and medical outcome post-immunotherapy
  • IO-7

    Disease

    Anti-PD1 Therapy Patients

    • Non-Small Cell Lung Cancer (NSCLC)

    Type and Number of Samples

    • Retrospective
    • 59 FFPE blocks of PD-L1 TPS between the range 5-20%
    • 28 FFPE blocks of PD-L1 TPS between the range 55-70%

    Specific Requirements

    • Any stage; Any subtype
    • FFPE blocks are to be evaluated for expression level (tumor proportion score (TPS)) of Programmed Death Ligand 1 (PD-L1)
    • FFPE blocks that allow the cutting of ≥ 50 sections of 4 µm
    • Tumor content ≥30%
    • Tissue samples fixed in 10% Neutral Buffered Formalin (NBF) between 12 to 72 hours

    Associated Data Required

    • Age, Gender
    • Date of sample collection
    • Confirmation of diagnosis along with histological subtype
    • PD-L1 TPS score (%)
    • Fixation time
  • IO-8

    Disease

    Anti-PD1 Therapy Patients

    • Non-Small Cell Lung Cancer (NSCLC)
    • Colorectal Carcinoma

    Type and Number of Samples

    • Retrospective
    • FFPE Blocks - total of 50 subjects
    • NSCLC Adenocarcinoma ALK positive (N=13)
    • NSCLC Adenocarcinoma PD-L1 (SP142) positive (N=7)
    • Colorectal Carcinoma MSH2 loss (N=15)
    • Colorectal Carcinoma MSH6 loss (N=15)

    Specific Requirements

    • Any stage; Any subtype
    • Tumor % ≥ 25%
    • Necrosis % < 40%
    • Minimum Slide Yield: 50 cuts

    Associated Data Required

    • Age, Gender
    • Year of collection
    • Site/origin of tissues
    • Pathology diagnosis
    • If primary or metastatic tumor
    • Tumor stage, grade
  • IO-9

    Disease

    Immune checkpoint inhibitor treatment

    • Late Stage Metastatic Melanoma (MM)

    Type and Number of Samples

    • Retrospective
    • FFPE blocks - 20 subjects

    Specific Requirements

    • Subjects with failed multiple lines of treatment (immune checkpoint inhibitor treatment failure preferred)
    • Samples from biopsies or surgical resections
    • Samples from primary or secondary (e.g. metastatic) tumors
    • Tumor content ≥ 30%
    • Necrosis ≤ 30%
    • Tissue samples fixed in 10% Neutral Buffered Formalin (NBF)

    Associated Data Required

    • Age, Gender
    • Sample Site (primary or secondary site)
    • Sample collection site (e.g. skin, brain, lung, liver)
    • Year of collection
    • Histological subtype
    • Tumor stage and grade
    • % tumor and % necrosis per sample
    • Patient treatment history
  • IO-10

    Disease

    Immune checkpoint inhibitor treatment

    • Non-Small-Cell Lung Carcinoma (NSCLC)

    Type and Number of Samples

    • Retrospective
    • FFPE Slides - 20 subjects
    • Group 1: Non-responders to immunotherapy (n=10)
    • Group 2: Non-responders to EGFR kinase inhibitor treatment (n=10)

    Specific Requirements

    • Subjects with high expression of PD-L1 (≥ 50% positive tumor cells) as per IHC analysis
    • Samples from core needle biopsies or surgical resections
    • Tissue samples fixed in 10 % Neutral Buffered Formalin (NBF)
    • Group 1: Non-responders to anti-PD-1/PD-L1 drugs (i.e. Opdivo®, Keytruda®, Tecentriq®, Imfinzi® or Libtayo®)
    • Group 2: Non-responders to EGFR kinase inhibitors (i.e. Tagrisso®, Iressa®, Tarceva®, Gilotrif®, Conmana®)

    Associated Data Required

    • Age, Gender
    • Year of collection
    • Pathological diagnosis with microscopic description (histological subtype)
    • Tumor stage and grade
    • Treatment history and medical outcome post-therapy
    • PD-L1 expression (IHC) data, if applicable
  • IO-11

    Disease

    Patients Responders to IO treatment

    • Head and Neck Squamous Cell Carcinoma (HNSCC)

    Type and Number of Samples

    • Retrospective
    • FFPE sections - 3 subjects
    • Per subject: 5 sections of 5 µm, 10 mm2 surface area
    • Per subject: H&E stained image matching the slide set

    Specific Requirements

    • Subjects must be treated with any immune checkpoint blockade monoclonal drugs (e.g. nivolumab, pembrolizumab etc.)
    • Subjects must be responding to anti PD1 treatment (i.e. partial response or complete response)
    • Biopsies or resection tissue samples fixed in 10% Neutral Buffered Formalin (NBF)
    • Tissue collected prior to anti-PD1 treatment

    Associated Data Required

    • Age, Gender
    • Year of collection
    • Pathological diagnosis with microscopic description (Histological Subtype)
    • Tumor Stage and Grade
    • Site of primary tumor
    • Treatment history and medical outcome post-immunotherapy (RECIST)
    • Patient Medical History, Medications
  • LC-02

    Disease

    Lung Cancer

    • Squamous cell lung carcinoma
    • Primary lung adenocarcinoma

    Type and Number of Samples

    • Tissue Microarrays (TMA); total of 1000 subjects
    • Squamous cell lung carcinoma (Stages I to IV) : 340 subjects
    • Primary lung adenocarcinoma (Stages I to IV): 660

    Specific Requirements

    • Retrospective
    • Main TMA: Adenocarcinioma : 2 cores at the center of tumour + 2 cores at tumour margin including inflammatory cells if observed. For each patient the first 2 cores (600 microns) punched at center + margin have to be placed near each together. Squamous cell lung carcinoma : 3 cores at the center of the tumour
    • 2nd MTA block (Replicates): Random location to differ from main block
    • General Specification for each TMA: 60-70 cores per TMA. Each core is 0.6mm TMAs prepared for each type of cancer and stage. 30 patients per TMA

    Associated Data Required

    • Age, Gender
    • Diagnostic and medical data
    • Stage (TNM, grade), % tumor cells in sample
    • Smoking status
    • Clinical history including Disease-free survival, Overall survival
  • LC-12

    Disease

    Lung Cancer

    • Non-Small Cell Lung Carcinoma
    • Metastatic

    Type and Number of Samples

    • Retrospective
    • Whole Blood, 11 subjects

    Specific Requirements

    • Stage IV NSCLC subjects
    • Chemotherapy naïve Donors

    Associated Data Required

    • Age, Gender
    • Diagnostic and medical data
    • Stage (TNM, grade)
    • Medical History and medical out-come
  • LC-17

    Disease

    Lung Cancer

    • Non-Small Cell Lung Carcinoma
    • EGFR mutation positive

    Type and Number of Samples

    • Prospective
    • Plasma, 50 subjects

    Specific Requirements

    • Patient previously treated or still treated with EGFR Tyrosine Kinase Inhibitor e.g. Gefitinib or Erlotinib
    • Responders or non-responders
    • Patients treated by TAGRISSO™(Osimertinib) were excluded
    • First line or second line of treatment

    Associated Data Required

    • Age, Gender
    • Sample collection date
    • Comprehensive pathology and clinical characteristics records
    • Smoking history
    • Treatment history
  • LC-18

    Disease

    Lung Cancer

    • Small Cell Lung Cancer (SCLC)

    Type and Number of Samples

    • Retrospective
    • FFPE Blocks, 175 subjects

    Specific Requirements

    • Stage I to IV
    • Primary tumors and secondary tumors

    Associated Data Required

    • Age, Gender, Ethinicity
    • Sample collection date
    • Pathological diagnosis with microscopic description
    • Tumor stage and grade
    • Origin/site of tumor
    • Patient Medical History
  • LC-20

    Disease

    Lung Cancer

    • Non-Small-Cell Lung Carcinoma (NSCLC)
    • Adenocarcinoma

    Type and Number of Samples

    • Retrospective
    • FFPE Blocks, 15 subjects
    • FFPE Blocks and Matched Plasma, 5 subjects

    Specific Requirements

    • Patients non-responders or progressors after 2 lines of standard of care (SOC) for the treatment of NSCLC (chemotherapy or biological therapy
    • Radiotherapy was excluded as line of treatment accepted
    • Biopsies or surgical resections

    Associated Data Required

    • Age, Gender
    • Sample collection date
    • Histopathological diagnosis
    • TNM stage
    • Description of treatment (e.g. chemotherapy protocol or checkpoint inhibitor therapy protocol)
    • Treatment history with chronology of treatments and sample collection (i.e. whether sample has been collected before or after treatment)
    • Treatment outcome
  • LC-21

    Disease

    Lung Cancer

    • Non-Small Cell Lung Carcinoma (NSCLC)
    • Adenocarcinomas and Squamous cell carcinomas

    Type and Number of Samples

    • Prospective
    • Matched sets of: Flash frozen tumor tissue, Plasma and Whole Blood
    • 20 subjects

    Specific Requirements

    • Biopsy
    • Stage I
    • Treatment naïve subjects

    Associated Data Required

    • Age, Gender, Ethinicity
    • Sample collection date
    • Subject Height (cm) and Weight (kg)
    • Diagnosis (cancer type and histological subtype)
    • Type of procedure used to obtain definitive diagnosis (e.g. FNA, open lung biopsy surgery)
    • Type of procedure used to obtain definitive diagnosis (e.g. FNA, open lung biopsy surgery)
    • TNM and stage
    • Treatment history
    • Mutation/hormonal status when data is available
  • LC-22

    Disease

    Lung Cancer

    • Non-Small Cell Lung Carcinoma (NSCLC) and Small Cell Lung Cancer (SCLC)

    Type and Number of Samples

    • Prospective
    • Plasma, 150 subjects

    Specific Requirements

    • Subjects that did not yet undergo any surgery, chemotherapy, radiation or any other treatment for this cancerous lesion (including, but not limited to systemic therapies)
    • Recent cancer staging should be within 90 days prior to baseline visit.
    • All stages

    Associated Data Required

    • Age, Gender, Ethinicity
    • Sample collection date
    • Height (cm) and Weight (kg)
    • Diagnostic method (Screening program/Symptoms suggestive of cancer/Following incidental findings/Other-specify)
    • Smoking status
    • CBC (Complete Blood Count), Hemoglobin level (g/dL), Mean Corpuscular Volume (MCV), Ferritin level
    • Existing comorbidity (yes or no): Chronic kidney disease, Renal failure, Cirrhosis (if yes – what is the reason? Alcohol, HBV, HCV), Diabetes, COPD, Autoimmune disease (if yes – which?)
    • Family history (cancer in first and second degree relatives)
    • Diagnosis – disease type and subtype
    • TNM and stage
    • Location of metastases (if any)
  • LC-23

    Disease

    Lung Cancer

    • Non-Small Cell Lung Carcinoma (NSCLC)

    Type and Number of Samples

    • Retrospective
    • FFPE blocks Matched blocks from pre- and post-treatment, 10 sets

    Specific Requirements

    • All subtypes and all stages
    • Primary tumors only
    • Both primary and/or metastatic tumors accepted for post-treatment FFPE blocks
    • Minimum tumor content: 30%

    Associated Data Required

    • Age, Gender
    • Diagnosis with histopathological subtype
    • Date of pre-treatment biopsy/resection
    • Date of post-treatment biopsy/resection
    • TNM amd stage
    • Treatment history
  • GI-2

    Disease

    Colorectal Cancer

    Type and Number of Samples

    • Prospective
    • FFPE Blocks and Matched Plasma, 200 subjects

    Specific Requirements

    • Newly Diagnosed patients with Colorectal Cancer stage IV
    • Known KRAS mutation status
    • Blood samples collected before treatment

    Associated Data Required

    • Age, Gender
    • Stage (TNM, grade)
    • KRAS mutation status
    • Treatment History and medical out-come
  • GI-5

    Disease

    Gastric Cancer

    • Poorly cohesive carcinoma and Normal Adjacent Tumor

    Type and Number of Samples

    • Retrospective
    • Frozen Tissue, 50 subjects

    Specific Requirements

    • Sample weight > 0.5g
    • Sample collected before neoadjuvant therapy or radiotherapy

    Associated Data Required

    • Age, Gender, Ethinicity
    • Sample collection date
    • Weight, height, BMI
    • Histologic type, Histologic grade, Pathologic staging (TNM)
    • Demographic, diagnostic and medical data
  • GI-7

    Disease

    Adenocarcinoma of the Esophagogastric Junction

    Type and Number of Samples

    • Retrospective
    • FFPE Blocks, subjects

    Specific Requirements

    • Stage IIIB or higher

    Associated Data Required

    • Age, Gender
    • Diagnostic and medical data
    • Stage (TNM, grade)
  • GI-19

    Disease

    Hereditary non-polyposis colorectal cancer (HNPCC)

    • Lynch syndrome

    Type and Number of Samples

    • Retrospective
    • FFPE Blocks, 10 subjects

    Specific Requirements

    • Confirmed loss of MSH6 expression
    • Any stage, Any grade, Any histological subtype
    • Resections only
    • Primary tumors only
    • Treated and untreated subjects

    Associated Data Required

    • Age, Gender
    • Year of collection
    • Histological subtype
    • Tumor Stage (TNM) and Grade
    • Method used for confirmation of MSH6 loss of expression
  • GI-20

    Disease

    Colorectal Cancer (CRC)

    • Esophageal Cancer
    • Gastric Cancer

    Type and Number of Samples

    • Prospective
    • EDTA plasma, 50 subjects

    Specific Requirements

    • Primary or recurrent cancer
    • Subjects who did not yet undergo any surgery, chemotherapy, radiation or any other treatment for this cancerous lesion (including, but not limited to systemic therapies)
    • Recent cancer staging should be within 90 days prior to baseline visit.

    Associated Data Required

    • Age, Gender, Ethinicity
    • Sample collection date
    • Height (cm), Weight (kg)
    • Method of diagnosis (Screening program/Symptoms suggestive of cancer/Following incidental findings/Other-specify)
    • Smoking status
    • CBC (Complete Blood Count), Hemoglobin level (g/dL), Mean Corpuscular Volume (MCV), Ferritin level
    • Presence of comorbidity: Chronic kidney disease, Renal failure, Cirrhosis (if yes – what is the reason? Alcohol, HBV, HCV), Diabetes, COPD, Autoimmune disease (if yes – which?)
    • Family history of cancer
  • GI-22

    Disease

    Cholangiocarcinoma (CC) (intra-hepatic (IHCC) and/ or extra- hepatic (EHCC))

    • Ampullary Papilla Cancer (APC)
    • Gallbladder Cancer (GBC)
    • Adenocarcinoma

    Type and Number of Samples

    • Retrospective
    • FFPE Blocks, 202 subjects

    Specific Requirements

    • Any stage, Any grade
    • Resections
    • Primary tumors and secondary tumors (i.e. metastatic) tumors from bile duct, gallbladder, or ampulla of Vater
    • Treated and/or untreated patients
    • Minimum tumor content ≥ 30%, Maximum necrosis ≤ 10%

    Associated Data Required

    Pathological diagnosis with microscopic description (Histological Subtype)

    • Age, Gender
    • Year of collection
    • Pathological diagnosis with microscopic description (Histological Subtype)
    • Tumor Stage and Grade
    • Site of primary, or secondary tumor (if applicable)